The U.S. Food and Drug Administration (FDA) released the results of its most recent safety review of the heart drug Multaq. In its review, which included studies done by the drug's manufacturer, Sanofi, the FDA found that Multaq is linked to higher rates of heart attack, stroke, and death in certain patients.
Multaq is currently prescribed to patients who have irregular heartbeats, which includes almost 10 percent of those over the age of 80. But as it turns out, the patients who are prescribed Multaq for their abnormal heartbeats are also those who have a greater risk of adverse cardiovascular events.
Federal health officials have issued a new warning label for the drug which highlights the increased risk of heart-related complications in patients who have abnormal heart rhythms. Multaq already carries the most serious type of warning because the drug can cause severe complications in people with recent heart failure.
For more information on dangerous drugs please visit our firm's website.